Medicare has begun covering obesity drugs for the first time, a significant policy shift offering access to millions of older Americans. Walmart and CVS Health are launching nationwide efforts to educate patients and provide support, including pharmacy consultations and virtual visits, to navigate the new coverage and manage treatments.
Medicare is launching the Bridge demonstration program to cover GLP-1 obesity drugs for eligible beneficiaries with a $50 monthly copay, a first for the program. This temporary initiative, set to expire in 2027, could unlock millions of new patients for Novo Nordisk and Eli Lilly, but raises concerns about healthcare system strain and long-term patient access.
Medicare's Bridge program starts covering obesity drugs for eligible beneficiaries with a $50 monthly copay, but 82% of older Americans are unaware of this new coverage.
Telehealth companies hired by employers to manage obesity drug costs are increasingly criticized for prioritizing cost-cutting over patient care. Patients report being forced to try less effective generic drugs or face denial of access to crucial medications like Zepbound and Wegovy, leading to frustration and weight regain.
Telehealth companies hired by employers to manage obesity drug costs are facing criticism for potentially limiting patient access to medications like Zepbound and Wegovy. Patients report being forced to try generic drugs first or facing hurdles that lead to out-of-pocket expenses, while doctors express concern over these companies offering medical advice outside their scope.
Anti-obesity drugs like GLP-1 analogues are altering consumer behavior, affecting sales of snacks, sodas, and meal replacements. Companies like Nestlé and Danone are acquiring meal substitute startups to adapt to these changes.
The FDA proposed excluding active ingredients in Novo Nordisk's Wegovy, Ozempic and Eli Lilly's Zepbound, Mounjaro from the list of drugs outsourcing facilities can compound in bulk. The proposal targets 503B facilities and would limit mass compounding unless the drugs appear on the FDA's shortage list. Public comments will be accepted until late June.
